



ASX Release

NZ MEDICAL CANNABIS – RESEARCH FACILITY APPROVAL

- JHL's wholly-owned NZ medical cannabis subsidiary, Whakaora Hou Limited (**WHL**), has received formal approval from the Tauranga City Council for the construction and fit-out of its medical cannabis research facility (**Research Facility**) at Papamoa, on the North Island of New Zealand.
- The construction and fit-out of the Research Facility is expected to commence in the next 2 weeks following the finalisation of the fixed-price construction contract and is expected to be completed in 6-8 weeks.
- WHL's application for the appropriate licenses for the operation of the Research Facility (**Licences**), and, subject to regulations being passed, commercially cultivate medical cannabis, is progressing with NZ's Ministry of Health.
- Commercial discussions to produce and/or license medical cannabis products for distribution via the Company's technology are ongoing, and subject to the granting of licences and regulation.

Melbourne, Australia: 8 May 2019: Jayex Healthcare Limited (**ASX:JHL**) (**JHL** or **Company**) today announces that its wholly-owned NZ medical cannabis subsidiary, Whakaora Hou Limited, has received approval from the Tauranga City Council to proceed with the construction and fit-out of its Research Facility at Papamoa, on the North Island of New Zealand.

The construction and completion of the fit-out of the Research Facility is a condition precedent to the granting by the NZ Ministry of Health to WHL of the Licences to permit the conduct by WHL of specific medical cannabis research activities prior to the expected passage in 2019 of the regulations required under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 (NZ) for the commercial scale cultivation of medical cannabis, production and manufacture of medical cannabis products and the prescribing, sale and distribution of those medical cannabis products in New Zealand.

The construction and fit-out of the Research Facility will take place under a fixed-price construction agreement. Finalisation of that contract and commencement of the construction and fit-out is expected to commence in the next 2 weeks, and the fit-out is expected to be completed within 6-8 weeks.

Following completion of the fit-out the Ministry of Health will inspect the completed Research Facility as part of the finalisation of WHL's application for the Licences.

Ends

Contacts for further information:

Investor Enquiries

Chief Executive Officer
Nick Fernando
1300 330 611
n.fernando@jayex.com

Company Secretary
Melanie Leydin
+61 3 9692 7222

Forward looking statements

This announcement contains forward-looking statements. All statements that address events or developments that we expect or anticipate will or may occur in the future are forward-looking statements. These forward-looking statements are based on the Board or management's beliefs and expectations based on information currently available to the Board and management. The Company believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements which are inherently uncertain. The Company does not undertake any obligation to publicly update or revised any forward-looking statements whether as a result of new information, future events or otherwise except as required by law or the ASX Listing Rules. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from the Company's historical experience, or present expectations or projections.

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider of integrated healthcare services delivery platforms in the United Kingdom and Australia, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
 - the *Appointuit* patient engagement solution;
 - the *Pharmacy Delivery 2 U (P2U)*[®] prescription delivery service; and
 - the *BluePoint*[®] remote pharmacy prescription processing and dispensing terminal.
-